CN106176953A - A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, Fructus Momordicae and Folium Mori - Google Patents
A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, Fructus Momordicae and Folium Mori Download PDFInfo
- Publication number
- CN106176953A CN106176953A CN201510214633.7A CN201510214633A CN106176953A CN 106176953 A CN106176953 A CN 106176953A CN 201510214633 A CN201510214633 A CN 201510214633A CN 106176953 A CN106176953 A CN 106176953A
- Authority
- CN
- China
- Prior art keywords
- group
- radix
- leaf
- health composition
- fructus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 230000036541 health Effects 0.000 title claims abstract description 34
- 241000233779 Cyclocarya paliurus Species 0.000 title claims abstract description 33
- 230000003345 hyperglycaemic effect Effects 0.000 title description 3
- 239000003814 drug Substances 0.000 claims abstract description 29
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 206010020772 Hypertension Diseases 0.000 claims abstract description 12
- 244000269722 Thea sinensis Species 0.000 claims abstract description 11
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 6
- 235000009569 green tea Nutrition 0.000 claims abstract description 5
- 201000001421 hyperglycemia Diseases 0.000 claims abstract description 5
- 235000006468 Thea sinensis Nutrition 0.000 claims abstract description 4
- 235000020279 black tea Nutrition 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims description 6
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 210000000582 semen Anatomy 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 235000011201 Ginkgo Nutrition 0.000 claims description 3
- 244000194101 Ginkgo biloba Species 0.000 claims description 3
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 3
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 235000008434 ginseng Nutrition 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 241001116389 Aloe Species 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 108010011485 Aspartame Proteins 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 240000000588 Hericium erinaceus Species 0.000 claims description 2
- 235000007328 Hericium erinaceus Nutrition 0.000 claims description 2
- 239000009636 Huang Qi Substances 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 241000180649 Panax notoginseng Species 0.000 claims description 2
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 241001506047 Tremella Species 0.000 claims description 2
- 235000011399 aloe vera Nutrition 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- 244000309464 bull Species 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims description 2
- -1 hydroxypropyl methyl Chemical group 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 235000013616 tea Nutrition 0.000 claims description 2
- 241000208340 Araliaceae Species 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 244000018795 Prunus mume Species 0.000 claims 1
- 235000011158 Prunus mume Nutrition 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 58
- 239000008280 blood Substances 0.000 abstract description 58
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 28
- 239000008103 glucose Substances 0.000 abstract description 28
- 230000000694 effects Effects 0.000 abstract description 25
- 230000008901 benefit Effects 0.000 abstract description 3
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 241000700159 Rattus Species 0.000 description 35
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 19
- 201000010099 disease Diseases 0.000 description 18
- 235000000346 sugar Nutrition 0.000 description 18
- 230000036772 blood pressure Effects 0.000 description 17
- 238000012360 testing method Methods 0.000 description 16
- 150000002632 lipids Chemical class 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- 235000013305 food Nutrition 0.000 description 14
- 206010012601 diabetes mellitus Diseases 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 102000004877 Insulin Human genes 0.000 description 11
- 108090001061 Insulin Proteins 0.000 description 11
- 229940125396 insulin Drugs 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000011160 research Methods 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- 102000001554 Hemoglobins Human genes 0.000 description 7
- 108010054147 Hemoglobins Proteins 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 7
- 240000003186 Stachytarpheta cayennensis Species 0.000 description 6
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 201000005577 familial hyperlipidemia Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 235000018927 edible plant Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 240000000249 Morus alba Species 0.000 description 3
- 235000008708 Morus alba Nutrition 0.000 description 3
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 240000005373 Panax quinquefolius Species 0.000 description 3
- 241000282894 Sus scrofa domesticus Species 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 108010028144 alpha-Glucosidases Proteins 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 235000014590 basal diet Nutrition 0.000 description 3
- 235000019636 bitter flavor Nutrition 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 210000002969 egg yolk Anatomy 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000000055 hyoplipidemic effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000008354 sodium chloride injection Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 108010001394 Disaccharidases Proteins 0.000 description 2
- 208000007530 Essential hypertension Diseases 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 101000637031 Homo sapiens Trafficking protein particle complex subunit 9 Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 102100031926 Trafficking protein particle complex subunit 9 Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 102000016679 alpha-Glucosidases Human genes 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 235000011073 invertase Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000000110 microvilli Anatomy 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000024287 Areas Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241001518926 Cladrastis Species 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 241000233778 Cyclocarya Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020660 Hyperlactacidaemia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 201000004239 Secondary hypertension Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 244000185386 Thladiantha grosvenorii Species 0.000 description 1
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- AHIBWURJLGCHAY-UHFFFAOYSA-N [S].C1=CC=CC=C1 Chemical compound [S].C1=CC=CC=C1 AHIBWURJLGCHAY-UHFFFAOYSA-N 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 229940069078 citric acid / sodium citrate Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000010159 dioecy Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 201000009939 hypertensive encephalopathy Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- 229960003243 phenformin Drugs 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 235000007063 yellowwood Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of health composition containing leaf of Cyclocarya paliurus Iljinskaja, Fructus Momordicae and Folium Mori, wherein the percentage by weight of three can be 1-98%:1-98%:1-98%.Described health composition can also comprise the one in the common Traditional Chinese medicine for reducing blood glucose such as Pericarpium Citri Reticulatae, Rhizoma Dioscoreae, green tea, Folium Ilicis, black tea or its combination in any.Present invention also offers the application in terms of preparation auxiliary treatment hyperglycemia, hypertension or hyperlipidemia health composition of the described health composition.The health composition of the present invention, based on natural drug, has no side effect, have clear curative effect, easy to use, have no side effect, synergism substantially and is prone to the advantages such as masses take.
Description
Technical field
The invention belongs to field of health care food, be specifically related to one and comprise leaf of Cyclocarya paliurus Iljinskaja, Fructus Momordicae and Folium Mori
Hyperglycemic health care compositions and preparation and purposes.
Background technology
Cyclocarya paliurus Iljinskaja (cyclocarya paliurus (Batal.) Ijinsk) is Juglandaceae cyclocarya plant, is
One of endangered plants of special-protection-by-the-State, it is a kind of tall and big fast-growing arbor, be distributed widely in Jiangxi,
The Changjiang river areass to the south such as Zhejiang, Hunan, Guangdong.Record according to " China book on Chinese herbal medicine ", have dispel the wind, antiinflammatory
The effect such as pain relieving and killing parasites for relieving itching.Its main component has saponin, flavone, terpenoid, polysaccharide, trace element
Deng.Leaf of Cyclocarya paliurus Iljinskaja taste is sweet, and research shows that leaf of Cyclocarya paliurus Iljinskaja has multiple efficacies: can substantially suppress lipase activity
Property, reduce digesting and assimilating of fat, and the metabolic breakdown of lipid material can be promoted；Can effectively reduce blood glucose,
It is obviously improved carbohydrate tolerance；Antioxidation, resisting fatigue.
Fructus Momordicae (Momordica Grosvenori Swingle), the perennial liana of Cucurbitaceae.
Another name LAHANGUO, Herba Cardiospermi Halicacabi, Semen Momordicae, Radix Stephaniae Sinicae (Radix Stephaniae Dielsianae), arhat table, naked Testudinis bar, be described as " god by people
Celestial fruit ", its leaf is heart-shaped, dioecism, summer-flowering, seed in autumn.Mainly originate in Zhuang nationality in Guangxi certainly
Longjiang township, Yongfu county, Zhi Qu Guilin City, dragon victory and hundred Shou Deng towns, He Longsheng county, Yongfu county is the township of Fructus Momordicae
Plantation history is longer, and wherein plantation Fructus Momordicae in Yongfu has had more than 300 year history, and Long Sheng county plants
Fructus Momordicae has had more than 200 year history, China's 90 percent Fructus Momordicae to originate in He Longsheng county, Yongfu county,
Fructus Momordicae is the local and special products that Guilin is famous and precious, is also one of first batch of medicine-food two-purpose material ratified of country, and it is main
Wanting effect is can relieving cough and resolving phlegm.Fruits nutrition is worth the highest, containing abundant vitamin C (every 100 grams fresh
Containing 400 milligrams～500 milligrams in Guo) and glucoside, fructose, glucose, protein, lipid etc..
Folium Mori (Mulberry Leaf, formal name used at school: Folium Mori) are the dried leaves of moraceae plants Mulberry,
Having another name called a Mulberry, Jing Sang, Fructus Mori tree, yellow wood leaf etc., mulberry is extensively planted in various places, China north and south, and Folium Mori produce
Amount is abundant.Gas is light, and mildly bitter flavor is puckery.Folium Mori are medicine-food two-purpose product, and Folium Mori among the people decoct juice for the bitter edible plant, research
Show that Folium Mori have the effect such as antihypertensive diuretic, blood fat reducing, energy Inhibiting α-glucosidase, and energy is competitive
Ground blocks the disaccharidase hydrolytic enzyme such as the maltase in small intestinal cell brush border and saccharase, makes to ingest
Polysaccharide, oligosaccharide and disaccharidase are digested to the absorption process of the monosaccharide such as glucose, fructose and are prevented from, thus drop
Low levels, plays effective blood sugar reducing function.
Diabetes are the endocrine and metabolic disorders diseases having genetic predisposition of a kind of common multi-pathogenesis, with
Growth in the living standard, its sickness rate, in the trend risen year by year, becomes the cancer that continues, cardiovascular and cerebrovascular vessel disease
The 3rd killer being detrimental to health after disease.The current research report display of 2012, China's glycosuria
Patient occupies the whole world first, and the U.S. estimates there are about the diabetics of more than 16,000,000, accounts for population total
The 6% of number.This disease such as can not get controlling, it will causes severe chronic complication and then disables lethal.Cause
This, the prophylactico-therapeutic measures strengthening diabetes is paid attention to by countries in the world, and research prevents and treats the novel of diabetes
Medicine and health food are the advanced subject of domestic and international association area.Non-medication treatment diabetes become
One of focus of medical science, threpsology, food scientific research now.The reason causing diabetes is no doubt a lot,
But it is also thing out of question that the living habit of China people and dietary structure make blood glucose be in higher state
Real.This has just become the risk groups that induced Diabetic is potential, the most great the most domestic enterprise and scientific research machine
Structure, falls over each other to research and develop hypoglycemic medicine or substitute products.Although product is a feast for the eyes, but the most all
Because of expensive, carrier is undesirable, effect is unstable or takes trouble and not by people's recognition and acceptance.
The drug main for the treatment of diabetes to have at present: 1, sulphanylureas Western medicine such as benzene sulphur hexamethylene urea, first sulphur pyrrole
Urea, glipizide, profit sugar is appropriate；2, biguanides: phenformin, metformin etc.；3, insulin is quick
Perception reinforcing agent class: pioglitazone, rosiglitazone etc.；4, insulin type and some treatment diabetes
Chinese patent medicine.Although western medicine effect is obvious, but side effect is big, as sulphanylureas for a long time with injury liver,
Kidney and hemocyte；Biguanides is for a long time with producing hyperlactacidemia, and insulin type is for a long time with being easily generated antibody.
Additionally, hypertension, hyperlipidemia are also puzzlements people " modern civilization diseases " in recent years, human body is good for
Health very harmful.Similar with diabetes to its difficulty prevented and treated.
Hyperlipemia (hyperlipemia), also known as hyperlipoproteinemia, can behave as hypercholesterolemia, high
Triacylglycerol mass formed by blood stasis or both have concurrently, it is with tremulous pulse medicated porridge sample hardening, diabetes, fatty liver, nephropathy etc.
Relation is the closest.Consequence is especially had day by day to cause people's in the morbidity of cardiovascular and cerebrovascular disease
Pay attention to.The traditional Chinese medical science thinks that hyperlipemia belongs to " turbid resistance ", " the phlegm-damp, " category such as obesity, " damp and hot ".
Hypertension is a kind of with the abnormal cardiovascular disease rising a height of principal character of arterial pressure.It is divided into by the cause of disease
Essential hypertension and secondary hypertension.The degree raised according to blood pressure, the quantity of risk factor, target
The degree of organ injury and and the clinical setting deposited hypertension was divided into for three phases: (1) mild hypertension:
Objective condition without organ injury；(2) moderate hypertension: an at least organ injury performance (left ventricle
Plumpness, arteria retina narrows, and albuminuria and serum creatinine raise, and ultrasonic examination has arteriosclerosis plaque)；
(3) severe hypertension: clinical manifestation (angina pectoris, myocardial infarction, the heart failure of organ injury occur
Exhaust, transient ischemic attack, apoplexy, hypertensive encephalopathy, retinal hemorrhage, renal failure, dynamic
Arteries and veins occlusive disease).Primary disease belongs to the categories such as " dizziness ", " headache " of the traditional Chinese medical science.
The " three high " cause of disease is complicated, and the current cause of disease is not completely clear and definite, doctor trained in Western medicine it is generally believed that mainly by:
Inherited genetic factors, environmental factors, the phase such as hyperinsulinemia and insulin resistant, obesity, Anomalous lipid metablism
Impact is caused mutually.Western medical treatment comparitive study is certainly at present, but the treatment being combined disease and complication thereof is stranded
Difficulty is relatively big, the side effect that degree is different simultaneously, and patient is often difficult to stand, it is impossible to adhere to treatment.The traditional Chinese medical science
Understanding and preventing and treating to above-mentioned disease, then start with from entirety conditioning, determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, although do not have
Western medicine is quick, but is nursed one's health by entirety, and symptom and index all can be effectively controlled, simultaneously can be effective
Protection target organ etc..Domestic a large amount of clinical data shows, Chinese medicine prevention and treatment " three high " and concurrent
Disease curative effect affirmative, and few side effects.From clinically, hyperlipidemia, hyperglycemia, hypertension are normal often
Merge and occur, reciprocal causation.Scientific research proves, slight long-term chronic hyperglycemia just can cause
The generation of all chronic complicating diseases, and long-term blood pressure increases, and again results in various diseases of cardiovascular and cerebrovascular systems
Generation.The traditional Chinese medical science is thought, modern " three high " patient shows as " deficiency of both vital energy and Yin, the expectorant stasis of blood is had a surplus " more, but
The Chinese patent medicine that can simultaneously treat " three high " at present is but known clearly very few, therefore, studies and develops and can prevent simultaneously
With treatment " three high " and the safely and effectively health-care combination of complication thereof for being the task of top priority, extremely urgent.
Although at present China produces that to have the kind of the medicine of function of polysaccharide and substitute products thereof a lot, but
Have and preferably have the pharmaceutical composition of blood sugar lowering, blood pressure lowering and lipid-lowering effect concurrently and but really belong to exception.?
Under such background, the present inventor is through long-term research practice, in immense medicine food raw material, logical
Cross a kind of guarantor with blood sugar lowering, blood pressure lowering and hypolipemic function of performing creative labour Development and Production
Strong compositions, and it is found surprisingly that the health composition of the present invention is to control through the test of pesticide effectiveness and analysis contrast
The blood glucose of diabetics and blood pressure lowering and blood fat reducing aspect create obvious synergism.
Summary of the invention
It is an object of the invention to provide one and have blood sugar lowering, blood pressure lowering and hypolipemic function concurrently, comprise green grass or young crops
The health composition of money Folium Salicis Babylonicae, Fructus Momordicae and Folium Mori, thus overcome drawbacks described above present in prior art.
On the one hand, the invention provides a kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja, Fructus Momordicae and Folium Mori,
Wherein the percentage by weight of leaf of Cyclocarya paliurus Iljinskaja, Fructus Momordicae and Folium Mori is 1-98%:1-98%:1-98%.
In one embodiment of the invention, the weight percent of described leaf of Cyclocarya paliurus Iljinskaja, Fructus Momordicae and Folium Mori
Ratio is 10-80%:10-80%:10-80%.
It is further preferred that the percentage by weight of described leaf of Cyclocarya paliurus Iljinskaja, Fructus Momordicae and Folium Mori is 20-60%:
20-60%:20-60%.
It is furthermore preferred that the percentage by weight of described leaf of Cyclocarya paliurus Iljinskaja, Fructus Momordicae and Folium Mori is 40%:40%:
20%.
In another embodiment of the present invention, described health composition can also comprise Pericarpium Citri Reticulatae, mountain
One in medicine, green tea, the Herba Lactucae formosanae bitter edible plant, black tea or its combination in any.
In yet another embodiment of the present invention, above-mentioned health composition also can comprise choosing the beautifulst
Bamboo, the Radix Paeoniae Alba, Poria, Radix Puerariae, Fructus Lycii, Rhizoma Polygonati, Thallus Laminariae (Thallus Eckloniae), Fructus Mume, Herba Dendrobii, Cortex Mori, Radix Ginseng,
Radix Notoginseng, Fructus Ligustri Lucidi, Fructus Corni, Rhizoma Chuanxiong, Rhizoma Atractylodis, Radix Scrophulariae, Radix Rehmanniae, Radix Angelicae Sinensis, Radix Rhodiolae, the West
Ginseng, Aloe, Fructus Schisandrae Chinensis, Radix Ophiopogonis, Radix et Rhizoma Rhei (processed), the Rhizoma Anemarrhenae, Fructus Tribuli, Folium Ginkgo, the Radix Astragali, Herb Gynostemmae Pentaphylli,
Fructus Momordicae charantiae, Radix Et Rhizoma Fagopyri Tatarici, Fructus Cucurbitae moschatae, Rhizoma amorphophalli, Herba Apii graveolentis, Stigma Maydis, Tremella, Hericium erinaceus (Bull. Ex Fr.) Pers. and Bulbus Allii are formed
One or more of in group.
In the present invention, described health composition can be carried out by the preparation method of any routine in this area
Preparation.
On the other hand, the invention provides described health composition at preparation auxiliary treatment hyperglycemia, high blood
Application in terms of pressure or hyperlipidemia health composition.
Another further aspect, the invention provides a kind of pharmaceutical preparation containing described health composition.
The health composition of the present invention can be prepared as any with pharmaceutically acceptable adjuvant as required
Suitably oral formulations is for blood sugar lowering, blood pressure lowering or the treatment of blood fat reducing.
In yet other embodiments, described oral formulations can be tablet, glue skirt agent,
The dosage forms such as granule, powder, effervescent, alternative tea and bagged steeping drug.
In another preferred embodiment of the present invention, described pharmaceutically acceptable adjuvant is the most permissible
Selected from pregelatinized Starch, beta-schardinger dextrin-, carbomer, microcrystalline Cellulose, hydroxypropyl methyl cellulose, low
Replace hydroxypropyl cellulose, Polyethylene Glycol (PEG), sodium carboxymethyl cellulose, methylcellulose, second
Base cellulose, mannitol, cross-linking sodium carboxymethyl cellulose, lactose, polyvinylpyrrolidone (PVP),
One in magnesium stearate, Pulvis Talci, micropowder silica gel, aspartame, sodium bicarbonate, sodium carbonate or more
Multiple.
Effect activity of each primary raw material medicine in the present invention
Leaf of Cyclocarya paliurus Iljinskaja: mildly bitter flavor, pungent, property is put down.Have invigorating the spleen for eliminating dampness, Clearing heat and removing obstruction of fu-organs, depressed liver-energy dispersing and QI regulating,
The effect of enriching yin and nourishing kidney, to because dysfunction of the spleen, expectorant are turbid, addiction delicious food savoury, lazy dynamic, abdominal distention food stagnation,
The liver silt stagnation of QI and the obesity that causes, have good improvement.
Fructus Momordicae: have refreshment, diuresis is recovered from fatigue, effect of fatigue alleviating, defying age, it is adaptable to
Rich food dish eats the crowd that too much person, hypertension, dysuria, heating are thirsty.
Folium Mori: gas is light, mildly bitter flavor is puckery.There is the effect such as antihypertensive diuretic, blood fat reducing, α-Fructus Vitis viniferae can be suppressed
Glycosidase, and it is double to block the maltase in small intestinal cell brush border and saccharase etc. competitively
Glycosylhydrolase, has blood sugar reducing function.
Pericarpium Citri Reticulatae: bitter in the mouth, pungent, warm in nature；Return lung, spleen channel；There is regulating qi-flowing for strengthening spleen, effect of drying dampness to eliminate phlegm,
For diseases such as distension and fullness in the abdomen, lack of appetite and vomiting, cough with copious phlegm.
Rhizoma Dioscoreae: sweet in the mouth, property are flat, return spleen, lung, kidney channel；Having spleen reinforcing nourishing the stomach, promote the production of body fluid lung benefiting, the kidney invigorating
Effect of arresting seminal emission, be used for treating insufficiency of the spleen, chronic diarrhea, the deficiency of the lung, suffer from a deficiency of the kidney, the disease such as leukorrhagia, frequent micturition.
The Radix Paeoniae Alba: cool in nature, bitter in the mouth is sour, is slightly cold, has blood-supplementing blood-nourishing, suppressing liver-YANG, easing the affected liver to relieve pain, holds back
Effects such as cloudy hidroschesis, it is adaptable to fever due to yin deficiency, menoxenia, the chest and abdomen pain over the hypochondriac region, extremity contraction suddenly, are rushed down
Dysentery stomachache, spontaneous sweating, metrorrhagia, the inferior disease of band.
Poria: sweet in the mouth, light, property is put down.GUIXIN, lung, spleen, kidney channel.There is promoting diuresis to eliminate damp pathogen, spleen invigorating,
Effect of mind calming.For edema oliguria, phlegm retention vertigo and palpitation, insufficiency of the spleen lack of appetite, loose stool has loose bowels, irritability,
The diseases such as palpitation with fear insomnia.
Radix Puerariae: sweet in the mouth, pungent, cool in nature.Attach to the lung and stomach meridians.Have expelling pathogenic factors from muscles for reducing heat, rash, promoting the production of body fluid to quench thirst,
Effect of yang invigorating antidiarrheal, the deficiency of YIN thirsty for exterior syndrome heating, stiff nape and back, measles without adequate eruption, calentura disappears
Yearningly, the disease such as diarrhea of heat type hematodiarrhoea, diarrhea due to hypofunction of the spleen.
The present invention has a following advantage:
The present inventor be found surprisingly that according to the present invention consumption proportion form containing leaf of Cyclocarya paliurus Iljinskaja, arhat
The health composition of fruit and Folium Mori has the excellent effect of blood sugar lowering, blood pressure lowering and blood fat reducing concurrently, and at fall blood
Sugar, blood pressure lowering and hypolipemic function aspect create obvious synergism.
Compared with prior art, the present invention is according to the character of traditional Chinese medicine of leaf of Cyclocarya paliurus Iljinskaja, at numerous Chinese medicines and food
In carried out a large amount of screening, thus obtained a kind of health care group comprising leaf of Cyclocarya paliurus Iljinskaja, Fructus Momordicae and Folium Mori
Compound, its have clear curative effect, easy to use, have no side effect, synergism substantially and is prone to popular
The advantage such as take.
Detailed description of the invention
To further describe the present invention below in detail.It is pointed out that following description is only to this
The illustration of the technical scheme that invention is claimed, the not any restriction to these technical schemes.This
The content that the protection domain of invention is recorded with appended claims is as the criterion.
Embodiment 1
Formula forms: leaf of Cyclocarya paliurus Iljinskaja 1.0kg, Fructus Momordicae 8.0kg, Folium Mori 1.0kg.
Preparation method:
2.1 accurately weigh each taste Chinese medicine according to above-mentioned formula, are crushed respectively by raw material, cross 60 mesh sieves, with
Remove raw material fine powder；
2.2 leaf of Cyclocarya paliurus Iljinskaja, Fructus Momordicae, Folium Mori are mixed in mixer about 20 minutes to mix homogeneously,
Obtain mixed material；
2.3 carry out subpackage, triangle bag-like by 1.5g/ bag, and packaging material are nylon membrane；
Embodiment 2
1, formula composition: leaf of Cyclocarya paliurus Iljinskaja 4.0kg, Fructus Momordicae 4.0kg, Folium Mori 2.0kg.
2, preparation method: with embodiment 1.
Embodiment 3
1, formula composition: leaf of Cyclocarya paliurus Iljinskaja 3.3kg, Fructus Momordicae 3.3kg, Folium Mori 3.3kg.
2, preparation method: with embodiment 1.
Embodiment 4
1, formula composition: leaf of Cyclocarya paliurus Iljinskaja 5.0kg, Fructus Momordicae 1.0kg, Folium Mori 1.0kg, Pericarpium Citri Reticulatae 1.0kg,
Rhizoma Dioscoreae 1.0kg, Radix Paeoniae Alba 1.0kg.
2, preparation method: with embodiment 1.
Embodiment 5
1, formula composition: leaf of Cyclocarya paliurus Iljinskaja 8.0kg, Fructus Momordicae 0.5kg, Folium Mori 0.5kg, Herba Lactucae formosanae bitter edible plant 0.5kg,
Black tea 0.5kg
2, preparation method: with embodiment 1.
Embodiment 6
1, formula composition: leaf of Cyclocarya paliurus Iljinskaja 1.0kg, Fructus Momordicae 1.0kg, Pericarpium Citri Reticulatae 1.0kg, Rhizoma Dioscoreae 1.0kg,
Green tea 1.0kg, Radix Scrophulariae 1.0kg, Radix Panacis Quinquefolii 1.0kg, Folium Ginkgo 1.0kg, Herb Gynostemmae Pentaphylli 1.0kg, Semen Maydis
Must 1.0kg.
2, preparation method: with embodiment 1.
Comparative example 1
Choose the sample as a comparison case 1 that leaf of Cyclocarya paliurus Iljinskaja 10kg is prepared by the preparation method in embodiment 1.
Comparative example 2
Choose the sample as a comparison case 2 that Fructus Momordicae 10kg is prepared by the preparation method in embodiment 1.
Comparative example 3
Choose the sample as a comparison case 3 that Folium Mori 10kg is prepared by the preparation method in embodiment 1.
Comparative example 4
Choose leaf of Cyclocarya paliurus Iljinskaja 3.5kg, green tea 3.5kg, Folium Mori 3.0kg by the preparation method in embodiment 1
The sample as a comparison case 4 prepared.
In above example, each component is commercial goods, can make described on pharmaceutics multiple dose
Type, capsule, granule, powder, tablet, oral liquid or the bag bubble bitter edible plant.
Experimental example 1: blood sugar lowering is tested
1, material and method
1.1 samples and reagent: sample prepared by embodiment 1-6 and comparative example 1-4, be respectively designated as S1,
S2, S3, S4, S5, S6 and D1, D2, D3, D4；Streptozotocin, SIGMA Products,
Specification: 1g/ props up, lot number: SLBJ7785V；Detection kit for insulin, import subpackage, Nanjing is built up
Bio-engineering corporation, 20141022；The sodium chloride injection (normal saline) of 0.9%, specification: 250ml/
Bottle, Kelun Pharm Ind Co., Ltd., Sichuan, lot number: C13102005-1；High lipid food formula (79%
Basal diet+1% cholesterol+15% fresh yolk+5% Adeps Sus domestica), picric acid etc..
1.2 instrument W-80A eddy mixers, Instrument Factory of Shanghai Medical Univ.'s product；Electronic balance, mettler
Toledo, made by mettler-toledo group, model: pl303；LDZ5-2 centrifuge, Beijing
Medical centrifuge factory；Johnson & Johnson surely person of outstanding talent's blood glucose meter (Johnson & Johnson (Chinese) medical device company limited)；BECKMAN
Synchron CX5 fully automatic blood biochemistry analyzer (U.S.)；Microplate reader, bio-rad (U.S.),
Model: iMark；DCA2000 type glycolated hemoglobin analysis, for Bayer A.G's product；
Other: platform balance, fixing cage etc..
1.3 laboratory animal SPF level SD rats, body weight 160～180g, male, big by south medical courses in general
Experimental Animal Center provides, the quality certification number: SCXK (Guangdong) 2011-0015.Animal is in SPF level barrier
Level Animal House is raised, and animal use credit number is: SYXK (Guangdong) 2012-0081.
1.4 dosage arrange adult's plan dosage and are 3.0g/60kg BW days, and human body 10 times amount is rat
Dosage, dosage is with crude drug gauge.
1.5 statistical analysis use SPSS17.0 statistical software to carry out data process, and parameter mean ±
Standard deviationRepresenting, comparing between group and use ANOVA variance analysis test, p ＜ 0.05 is for there being statistics
Learn difference.
2. method and result
2.1 method
2.1.1 rat feed normal diet: Semen Maydis powder 80%, flour 15%, analysis for soybean powder 5%；High fat
Feedstuff: 79% basal diet+1% cholesterol+15% fresh yolk+5% Adeps Sus domestica.
2.1.2 modeling: take 160-180gSPF level SD rat 120, male, body weight 160～180g,
Adaptability takes 10 after feeding one week and is only used as Normal group, feeds with chow diet, and other respectively organizes elder generation
Feed 1 month with high lipid food, after selective examination blood lipids index is significantly raised, lumbar injection STZ 35mg/kg
(STZ is before use by the citric acid/sodium citrate buffering of 0.1mmol/LpH=4.5 for induced Diabetic model
Liquid is made into the solution of 6mg/mL, and is finished in 60min).7d after injection, docking gathers sky
Abdomen venous blood, measures blood glucose with blood glucose meter, is considered as being modeled as more than or equal to 16.7mmol/L by blood glucose value
Merit.After model stability, according to blood-fat and blood sugar height packet, it is orally administered to test medicine and control drug,
Observe indices.
2.1.3 it is grouped and is administered: preferable 110 the modeling success animals of state of choosing are according to blood glucose value and body
Weight average is even is divided into 11 groups: often group 10, i.e. type ii diabetes model control group (giving distilled water),
S1 group, S2 group, S3 group, S4 group, S5 group, S6 group, D1 group, D2 group, D3 group and D4 group.
The SD rat 10 of normal not modeling is Normal group (giving distilled water).Each group is by corresponding dosage
Oral administration, is administered once daily, dosage period: 4 weeks (4W).
2.2 testing index
2.2.1 use blood glucose meter respectively measure administration before and be administered after 2W and 4W blood glucose value.
2.2.2 serum insulin, saccharification hemoglobin content are detected.
2.2.3 carbohydrate tolerance test: terminate a few days ago to detect in experiment；Carbohydrate tolerance detects: animal fasting
About 6 little, time, each group gives variable concentrations given the test agent, oral administration of glucose 2.0g/kg after 15-20 minute,
Measuring to the blood glucose value of after glucose 0,0.5,2 hours, observing and nursing matched group is given with given the test agent group
The change of each time point Area under the curve of blood glucose after glucose.Area under the curve of blood glucose=1/2 × (0 hour blood
Sugar value+0.5 hours blood glucose value) × 0.5+1/2 × (2 hours blood glucose value+0.5 hours blood glucose value) × 1.5=
0.25 × (0 hours blood glucose value+4 × 0.5 hours blood glucose value+3 × 2 hours blood glucose value)
2.3 result
2.3.1 the impact on type ii diabetes rat blood sugar
From table 1, comparing with Normal group, it is notable that the front Glycemia Decline of administration respectively organizes rat blood sugar
Raise, show diabetes model modeling success.After being administered 2w, compare with model control group, S1-S6
Group, D1 group and D4 group blood glucose all have decline.After being administered 4w, S1-S6 group, D1 group and D4 group blood
Sugar all has decline.
The impact on type ii diabetes rat blood sugar of table 1. sample
Note: compare with Normal group:#P ＜ 0.05,##P ＜ 0.01；Compare with model group:*P ＜ 0.05,*P ＜ 0.01
2.3.2 on type ii diabetes rat blood serum insulin and the impact of glycolated hemoglobin
From table 2, comparing with Normal group, model control group feeds high lipid food and Glycemia Decline
After, rat blood serum insulin substantially reduces (p ＜ 0.01), glycolated hemoglobin significantly raised (p ＜ 0.01),
Show olive Antihyperlipidemia capsule modeling success.Compare with model control group, S1-S6 group, D1 group and
D4 group serum insulin all has increase.Compare with model control group, S1-S6 group, D1 group and D4 group sugar
Change hemoglobin and all have decline (comparing P ＜ 0.05 with model group).
Table 2. sample is on type ii diabetes rat blood serum insulin and the impact of glycolated hemoglobin
| Group | n | Insulin (mmol/L) | Glycolated hemoglobin (mmol/L) |
| Normal group | 10 | 18.91±2.84 | 3.86±0.61 |
| Model control group | 10 | 9.03±2.27## | 9.42±1.30## |
| S1 group | 10 | 13.76±2.46* | 7.41±1.32* |
| S2 group | 10 | 13.71±2.64* | 7.44±1.48* |
| S3 group | 10 | 14.01±2.89* | 7.33±1.76* |
| S4 group | 10 | 13.52±3.06* | 7.37±1.53* |
| S5 group | 10 | 13.28±2.64* | 7.43±1.68* |
| S6 group | 10 | 13.58±2.60* | 7.33±1.59* |
| D1 group | 10 | 13.20±2.61* | 7.50±1.75* |
| D2 group | 10 | 11.03±2.86 | 8.54±2.62 |
| D3 group | 10 | 10.92±2.73 | 8.62±1.97 |
| D4 group | 10 | 12.97±2.10 | 7.69±1.28* |
Note: compare with Normal group:#P ＜ 0.05,##P ＜ 0.01；Compare with model group:*P ＜ 0.05,*P ＜ 0.01
2.3.3 to type ii diabetes rat carbohydrate tolerance test result
From table 3, compare with model control group, S1-S6 group, D1 group and the blood glucose curve of D4 group
Lower area all has decline.
Table 3. sample is to type ii diabetes rat carbohydrate tolerance test result
| Group | n | Area under the curve of blood glucose |
| Normal group | 10 | 13.45±1.14 |
| Model control group | 10 | 38.86±5.87## |
| S1 group | 10 | 31.47±5.83* |
| S2 group | 10 | 31.62±5.72* |
| S3 group | 10 | 27.21±5.53** |
| S4 group | 10 | 32.52±6.40* |
| S5 group | 10 | 32.19±5.82* |
| S6 group | 10 | 31.84±6.03* |
| D1 group | 10 | 32.12±5.86* |
| D2 group | 10 | 35.62±6.72 |
| D3 group | 10 | 36.83±6.38 |
| D4 group | 10 | 33.28±6.19* |
Note: compare with Normal group:#P ＜ 0.05,##P ＜ 0.01；Compare with model control group: p is equal
More than 0.05.
3. conclusion: S1-S6, D1 and D4 have obvious hypoglycemic activity to diabetic model rats,
And the compositions of S1-S6 creates significant synergy in terms of blood sugar lowering.
Experimental example 2: lipid-lowering test
1, material and method
1.1 medicines and reagent: sample prepared by embodiment 1-6 and comparative example 1-4, be respectively designated as S1,
S2, S3, S4, S5, S6 and D1, D2, D3, D4；Sodium chloride injection (the physiology salt of 0.9%
Water), specification: 250ml/ bottle, Kelun Pharm Ind Co., Ltd., Sichuan, lot number: C13102005-1；
High lipid food formula (79% basal diet+1% cholesterol+15% fresh yolk+5% Adeps Sus domestica), distilled water,
Picric acid, etc..
1.2 instrument W-80A eddy mixers, Instrument Factory of Shanghai Medical Univ.'s product；Electronic balance, mettler
Toledo, made by mettler-toledo group, model: pl303；LDZ5-2 centrifuge, Beijing
Medical centrifuge factory；BECKMAN Synchron CX5 fully automatic blood biochemistry analyzer (U.S.)；
Other: platform balance, fixing cage etc..
1.3 laboratory animal SPF level SD rats, body weight 160～180g, male, big by south medical courses in general
Experimental Animal Center provides, the quality certification number: SCXK (Guangdong) 2011-0015.Animal is in SPF level barrier
Level Animal House is raised, and animal use credit number is: SYXK (Guangdong) 2012-0081.
1.4 dosage arrange adult's plan dosage and are 3.0g/60kg BW days, and human body 10 times amount is rat
Dosage, dosage is with crude drug gauge.
1.5 statistical analysis use SPSS17.0 statistical software to carry out data process, and parameter mean ±
Standard deviation (x ± s) represents, comparing between group and use ANOVA variance analysis test, p ＜ 0.05 is for there being statistics
Learn difference.
2. method and result
2.1 packets take SPF level SD rat 120 with method, male, and body weight 160～180g is suitable
Answering property takes 10 after feeding one week and is only used as Normal group, feeds with chow diet；Residue gives high fat
Forage feed.Continuous nursing 4 weeks (determining that modeling is the most successful by timing blood drawing detection four items of blood lipid tests)
After, preferable 110 the modeling success animals of state of choosing uniformly are divided into 11 according to blood fat numerical value and body weight
Group: often group 10, i.e. hyperlipemia model matched group (giving distilled water), S group, S2 group, S3
Group, S4 group, S5 group, S6 group, D1 group, D2 group, D3 group and D4 group.
High lipid food is started to be administered and continue (just feeding high lipid food by above packet situation after feeding 4 weeks
Often matched group feeds normal diet), every day 1 time, successive administration 4w.After last is administered, fasting overnight,
After next day weighs in, chloral hydrate anesthesia, put to death after postcava blood sampling.Take supernatant after Li Xin to survey
Biochemical indicator in serum.
2.2 Testing index:
(1) general status is observed, and records body weight weekly.
(2) each group rat blood serum lipid index: orbital venous plexus takes blood every two weeks, separation Virus monitory:
T-CHOL (TC), triglyceride (TG), high density lipoprotein (HDL-C), low density lipoprotein, LDL
(LDL-C)。
2.3 result
2.3.1 on the impact of TC, TG, HDL-C, LDL-C in serum
Iipid data in rat blood serum after table 4. modeling success even group-division
Note: compare with Normal group:#P ＜ 0.05,##P ＜ 0.01；Compare with model control group: p is equal
More than 0.05.
Table 5. is each after being administered 2W organizes Iipid data in rat blood serum
Note: compare with Normal group:#P ＜ 0.05,##P ＜ 0.01；Compare with model group:*P ＜ 0.05,*P ＜ 0.01
Table 6. is each after being administered 4W organizes Iipid data in rat blood serum
Note: compare with Normal group:#P ＜ 0.05,##P ＜ 0.01；Compare with model group:*P ＜ 0.05,*P ＜ 0.01
From table 4, compare with Normal group, after model control group feeds high lipid food 4W, rat
Serum TC, LDL-C significantly raise (p ＜ 0.01), TG significantly raised (p ＜ 0.05), show hyperlipemia
Disease rat model modeling success.4 groups uniformly it are divided into according to blood lipid level.
From table 5, after being administered 2W, compare with model control group, S1-S6 group, D1 group and D4
Group all has the effect reducing lipids in serum level.
From table 6, after being administered 4W, compare with model control group, S1-S6 group, D1 group and D4
Group can reduce TC, TG, LDL-C level in serum (p ＜ 0.05 or p ＜ 0.01).
3. conclusion: S1-S6, D1 and D4 have obvious effect for reducing blood fat to Hyperlipemia model rat,
And the compositions of S1-S6 creates significant synergy in terms of blood fat reducing.
Experimental example 3: blood pressure lowering is tested
1, material and method
1.1 medicines and reagent: sample prepared by embodiment 1-6 and comparative example 1-4, be respectively designated as S1,
S2, S3, S4, S5, S6 and D1, D2, D3, D4；Sodium chloride injection (the physiology salt of 0.9%
Water), specification: 250ml/ bottle, Kelun Pharm Ind Co., Ltd., Sichuan, lot number: C13102005-1；
Distilled water, picric acid, etc..
1.2 instrument DKB-501A type super constant temperature water tanks, reliable test Instrument Ltd. for Shanghai is gloomy
Product；Constant Temp. Oven, for Changsha medical apparatus and instruments factory product；Powlab/4sp ML125 type without
Wound pressure measuring system (ML125/R NIBP, MLT1199 BPTrans-ducer/Cable Kit), Australia is big
Leah Ai De Instrument Ltd. product；MP120-1 electronic balance, for Shanghai Second Balance Factory
Product.
1.3 laboratory animal SPF level SHR rats, body weight 190～230g, male, logical by Beijing dimension
Li Hua laboratory animal Technology Co., Ltd. provides, the quality certification number: SCXK (capital) 2012-0001.Animal in
SPF level barrier level Animal House is raised, and animal use credit number is: SYXK (Guangdong) 2012-0081,
SPF level WISTAR male rat, Beijing Vital River Experimental Animals Technology Co., Ltd. provides, real
Testing animal productiong credit number is: SCXK (capital) 2012-0001.
1.4 dosage arrange adult's plan dosage and are 3.0g/60kg BW days, and human body 10 times amount is rat
Dosage, dosage is with crude drug gauge.
1.5 statistical analysis use SPSS17.0 statistical software to carry out data process, and parameter mean ±
Standard deviation (x ± s) represents, comparing between group and use ANOVA variance analysis test, p ＜ 0.05 is for there being statistics
Learn difference.
2. method and result
11 groups are divided at random, often group 10 by male for 9-10 week old spontaneous hypertensive rat (SHR),
I.e. hypertension model matched group (giving distilled water), S group, S2 group, S3 group, S4 group, S5 group,
S6 group, D1 group, D2 group, D3 group and D4 group.It is normal for separately taking normal WISTAR rat 10
Matched group (gives distilled water).Each treated animal gavage respectively gives various dose drug, every day 1 time,
It is administered 4 weeks altogether.Within 2 weeks, 4 weeks, examine with noinvasive arteria caudalis pressure measuring system before being administered and after being administered
Survey rat tail artery pressure value (shrinking pressure, SAP, mmHg).
Noinvasive tail sleeve method (NIBP): rat is put into rat fixator, exposes rat-tail.Take with infrared
Warmer, temperature is set to 38 DEG C, and after irradiating heating rat-tail about 10min, rat-tail deliquescing, rat-tail is moved
Arteries and veins is fully expanded.Be passed through pressurizeing tail sleeve and being fixed on the root of rat-tail, make rat tail artery with
PowerlabML125/R noinvasive arteria caudalis blood pressure determination is analyzed the pulse transducer of system and is in close contact, with
Time observation system pulse wave, can start when stable pulse wave occurs to measure blood pressure.Treat that animal is pacified
After quiet, select 90～420BPM (rat pressurization shelves) to tail sleeve inflating pressure, it is seen that pulse wave gradually subtracts
Little to disappearing, then tail sleeve starts venting, and Mus set pressure reduces, and when pressure is equal to when shrinking pressure, starts
Pulse wave occur, the pressure value of this point is rat-tail and shrinks pressure.Repeated measure 3 times, averages.Meter
Calculating voltage drop value (drop-out value of blood pressure), before after administration, SAP deducts administration, SAP obtains.The results are shown in Table 7:
The impact to SHR rat blood pressure (SAP, mmHg) of table 7 sample
Note: compare with Normal group: # is P ＜ 0.01；Compare with model control group: * is P ＜ 0.05.
Result shows, compares with Normal group, and model control group rat blood pressure significantly raises, it is seen that from
The success of Essential hypertension rat model.With model control group, S1-S6 group, D1 group and D4 group are being administered
4W can significantly reduce the blood pressure (P ＜ 0.05) of SHR rat.
3. conclusion: S1-S6, D1 and D4 sample has significant hypotensive activity, and the combination of S1-S6
Thing creates significant synergy in terms of blood pressure lowering.
Present invention merely illustrates some claimed specific embodiments, one of them or
Technical characteristic described in more technical schemes can be with arbitrary one or more technical scheme phases
Combination, these are combined and the technical scheme that obtains also in the application protection domain, just as these are through group
As the technical scheme closed and obtain specifically is recorded in the disclosure of invention.
Claims (10)
1. comprise a health composition for leaf of Cyclocarya paliurus Iljinskaja, wherein comprise leaf of Cyclocarya paliurus Iljinskaja, Fructus Momordicae and
Folium Mori.
Health composition the most according to claim 1, it is characterised in that described leaf of Cyclocarya paliurus Iljinskaja,
The percentage by weight of Fructus Momordicae and Folium Mori be the leaf of Cyclocarya paliurus Iljinskaja of 1-98%, the Fructus Momordicae of 1-98% and
The Folium Mori of 1-98%.
Health composition the most according to claim 1 and 2, it is characterised in that described blue or green money
The percentage by weight of Folium Salicis Babylonicae, Fructus Momordicae and Folium Mori is the arhat of the leaf of Cyclocarya paliurus Iljinskaja of 10-80%, 10-80%
Fruit and the Folium Mori of 10-80%.
4. according to the health composition described in any one of claim 1-3, it is characterised in that Cyclocarya paliurus Iljinskaja
The percentage by weight of leaf, Fructus Momordicae and Folium Mori is the Fructus Momordicae of the leaf of Cyclocarya paliurus Iljinskaja of 20-60%, 20-60%
Folium Mori with 20-60%.
5. according to the health composition described in any one of claim 1-4, it is characterised in that described group
Compound also comprises the one in Pericarpium Citri Reticulatae, Rhizoma Dioscoreae, green tea, Folium Ilicis, black tea or its combination in any.
6. according to the health composition described in any one of claim 1-5, it is characterised in that described group
Compound also comprises choosing free Rhizoma Polygonati Odorati, the Radix Paeoniae Alba, Poria, Radix Puerariae, Fructus Lycii, Rhizoma Polygonati, Thallus Laminariae (Thallus Eckloniae), crow
Prunus mume (sieb.) sieb.et zucc., Herba Dendrobii, Cortex Mori, Radix Ginseng, Radix Notoginseng, Fructus Ligustri Lucidi, Fructus Corni, Rhizoma Chuanxiong, Rhizoma Atractylodis, Radix Scrophulariae,
Radix Rehmanniae, Radix Angelicae Sinensis, Radix Rhodiolae, Radix Panacis Quinquefolii, Aloe, Fructus Schisandrae Chinensis, Radix Ophiopogonis, Radix et Rhizoma Rhei (processed), the Rhizoma Anemarrhenae,
Fructus Tribuli, Folium Ginkgo, the Radix Astragali, Herb Gynostemmae Pentaphylli, Fructus Momordicae charantiae, Radix Et Rhizoma Fagopyri Tatarici, Fructus Cucurbitae moschatae, Rhizoma amorphophalli, Herba Apii graveolentis, Semen Maydis
One or more of in the group that palpus, Tremella, Hericium erinaceus (Bull. Ex Fr.) Pers. and Bulbus Allii are formed.
7. the health composition described in any one of claim 1-6 is in preparation treatment hyperglycemia, hypertension
Or the application in hyperlipidemia health composition.
8. comprise a pharmaceutical preparation for health composition described in any one of claim 1-6, wherein
Described health composition and pharmaceutically acceptable adjuvant are prepared as oral formulations.
Pharmaceutical preparation the most according to claim 8, wherein said oral formulations is tablet, glue
Wafer, granule, powder, effervescent, alternative tea or bagged steeping drug.
Pharmaceutical preparation the most according to claim 8 or claim 9, wherein said pharmaceutically acceptable
Adjuvant is selected from pregelatinized Starch, beta-schardinger dextrin-, carbomer, microcrystalline Cellulose, hydroxypropyl methyl fiber
Element, low-substituted hydroxypropyl cellulose, Polyethylene Glycol (PEG), sodium carboxymethyl cellulose, methyl are fine
Dimension element, ethyl cellulose, mannitol, cross-linking sodium carboxymethyl cellulose, lactose, polyvinylpyrrolidine
Ketone (PVP), magnesium stearate, Pulvis Talci, micropowder silica gel, aspartame, sodium bicarbonate, carbonic acid
One or more of in sodium.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510214633.7A CN106176953A (en) | 2015-04-29 | 2015-04-29 | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, Fructus Momordicae and Folium Mori |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510214633.7A CN106176953A (en) | 2015-04-29 | 2015-04-29 | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, Fructus Momordicae and Folium Mori |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106176953A true CN106176953A (en) | 2016-12-07 |
Family
ID=57457633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510214633.7A Withdrawn CN106176953A (en) | 2015-04-29 | 2015-04-29 | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, Fructus Momordicae and Folium Mori |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106176953A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107136269A (en) * | 2017-06-29 | 2017-09-08 | 北京颐方生物科技有限公司 | A kind of blue or green money willow bitter gourd sugar-reducing tea and preparation method thereof |
| CN107372947A (en) * | 2017-06-21 | 2017-11-24 | 武汉市元大生物科技有限公司 | One kind bubble pocket type blood-sugar reducing tea and preparation method thereof |
| CN108887648A (en) * | 2018-07-13 | 2018-11-27 | 安徽黑娃食品科技有限公司 | A kind of original fragrance sunflower seeds and preparation method thereof |
| CN112120204A (en) * | 2020-10-27 | 2020-12-25 | 湖南华诚生物资源股份有限公司 | Sweet composition for reducing blood fat and preparation method thereof |
| CN114832063A (en) * | 2022-06-07 | 2022-08-02 | 廖志航 | Composition with function of regulating blood sugar, blood fat and/or uric acid |
| CN115956617A (en) * | 2022-12-20 | 2023-04-14 | 里森食品(广州)有限公司 | A kind of mulberry leaf corn silk tea based on hypoglycemic function orientation and preparation method thereof |
-
2015
- 2015-04-29 CN CN201510214633.7A patent/CN106176953A/en not_active Withdrawn
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107372947A (en) * | 2017-06-21 | 2017-11-24 | 武汉市元大生物科技有限公司 | One kind bubble pocket type blood-sugar reducing tea and preparation method thereof |
| CN107136269A (en) * | 2017-06-29 | 2017-09-08 | 北京颐方生物科技有限公司 | A kind of blue or green money willow bitter gourd sugar-reducing tea and preparation method thereof |
| CN108887648A (en) * | 2018-07-13 | 2018-11-27 | 安徽黑娃食品科技有限公司 | A kind of original fragrance sunflower seeds and preparation method thereof |
| CN112120204A (en) * | 2020-10-27 | 2020-12-25 | 湖南华诚生物资源股份有限公司 | Sweet composition for reducing blood fat and preparation method thereof |
| WO2022088540A1 (en) * | 2020-10-27 | 2022-05-05 | 湖南华诚生物资源股份有限公司 | Blood lipid-lowering sweetener composition and preparation method therefor |
| CN114832063A (en) * | 2022-06-07 | 2022-08-02 | 廖志航 | Composition with function of regulating blood sugar, blood fat and/or uric acid |
| CN114832063B (en) * | 2022-06-07 | 2023-09-22 | 廖志航 | A composition with blood sugar, blood lipid and/or uric acid regulating effect |
| CN115956617A (en) * | 2022-12-20 | 2023-04-14 | 里森食品(广州)有限公司 | A kind of mulberry leaf corn silk tea based on hypoglycemic function orientation and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106176918A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Radix Puerariae | |
| CN104435775A (en) | Chinese medicinal health-care spirit and preparation method thereof | |
| CN106176953A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, Fructus Momordicae and Folium Mori | |
| CN106177183A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, green tea and Folium Mori | |
| CN102526478B (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
| CN106492073A (en) | A kind of Chinese medicine composition with uric acid resisting effect and its preparation method and application | |
| CN104147385B (en) | A kind of formula of Chinese medicine for lowering blood pressure preparation and preparation method | |
| CN102526479A (en) | Health-care medicine formula with functions of enhancing immunity and lowering blood sugar | |
| CN101444303B (en) | Dendrobium kudzu eucommia bark functional food | |
| CN106177053A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Pericarpium Citri Reticulatae | |
| CN108578544A (en) | A kind of Chinese medicine composition and the preparation method and application thereof with blood sugar reducing function | |
| CN106176952A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja and Folium Ilicis | |
| CN106177432A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja, Folium Mori, green tea and Rhizoma Polygonati Odorati | |
| CN106177433A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, Radix Puerariae and Rhizoma Polygonati Odorati | |
| CN106177477A (en) | A kind of health composition for blood sugar lowering, blood fat reducing and blood pressure lowering | |
| CN104857154A (en) | Traditional Chinese medicine composition for treating three-high diseases and preparation method therefor | |
| CN106177434A (en) | A kind of Hyperglycemic health care compositions comprising Radix Puerariae and Rhizoma Polygonati Odorati | |
| CN106173605A (en) | A kind of Hyperglycemic health care compositions comprising Radix Puerariae and Herba Dendrobii | |
| CN108967882A (en) | Gastrodia tuber noodles with health role and preparation method thereof | |
| CN104206595A (en) | Blood lipid and blood glucose reducing Chinese wolfberry root-bark health care tea and preparation method thereof | |
| CN106177054A (en) | A kind of Hyperglycemic health care compositions comprising Cortex Mori and Pericarpium Citri Reticulatae | |
| CN106177479A (en) | A kind of Hyperglycemic health care compositions comprising Herba Dendrobii and Rhizoma Polygonati Odorati | |
| CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
| CN104825821A (en) | Medicine for treating diabetes and preparation method thereof | |
| CN105056103A (en) | Steamed buns with assistant effect of reducing blood fat and cholesterol and processing method of steamed buns |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20161207 |